Neuron-specific enolase and lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 6, 2005, Pages 586-590

  Karnak, Demet ^a   Beder, Sumru ^a   Kayacan, Oya ^a   Íbiş, Erkan ^a   Oflaz, Gül ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Bronchoalveolar lavage fluid; Lung cancer; Neuron specific enolase; Tumor marker

Indexed keywords

NEURON SPECIFIC ENOLASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; LUNG CANCER; LUNG LAVAGE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; SENSITIVITY AND SPECIFICITY; SMOKING;

ADOLESCENT; ADULT; AGED, 80 AND OVER; BLOOD UREA NITROGEN; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEMOPTYSIS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PHOSPHOPYRUVATE HYDRATASE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SENSITIVITY AND SPECIFICITY; SMOKING; TUMOR MARKERS, BIOLOGICAL;

EID: 29044443602     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000177915.51805.6e     Document Type: Article

References (43)

1. Burghuber OC, Worofka B, Schernthoner G, et al. Serum neuron-specific enolase is a useful tumor marker for small-cell lung cancer. Cancer. 1990;65:1386-1390.
2. Dowlati A, Bury T, Corhay JL, et al. High neuron specific enolase levels in bronchoalveolar lavage fluid of patients with lung carcinoma: diagnostic value, relation to serum neuron specific enolase, and staging. Cancer. 1996;77:2039-2043.
3. Dowlati A, Loo M, Burry T, et al. Soluble and cell-associated transferrin receptor in lung cancer. Br J Cancer. 1997;75:1082-1086.
4. Bonner JA, Sloan JA, Rowland BCM, et al. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer. Clin Cancer Res. 2000;6:597-601.
5. Cooper EH, Splinter TA, Brown DA, et al. Evaluation of a radioimmunoassay for neuron-specific enolase in small-cell lung cancer. Br J Cancer. 1985;52:333-338.
6. Gronowitz JS, Bengström R, Nôu E, et al. Clinical and serologic markers of stage and prognosis in small-cell lung cancer. Cancer. 1990;66:722-732.
7. Akoun GM, Scarna HM, Milleron BJ, et al. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small lung cancer. Chest. 1985;87:39-43.
8. Carney DN, Marangos PJ, Ihde DC, et al. Serum neuron-specific enolase: a marker for disease extent and response to therapy of small lung cancer. Lancet. 1982;i:583-585.
9. Pina TC, Zapata IT, Hernandez FC, et al. Tumor markers in serum, bronchoalveolar lavage and biopsy cytosol in lung carcinoma: what environment lends the optimum diagnostic yield? Clin Chim Acta. 2001;305:27-34.
10. Prados MC, Alvarez-Sala R, Terreros Caro FJ, et al. The concentrations of five tumor markers in both BAL fractions in lung cancer patients in relation to cigarette smoking. Tumori. 1999;85:454-457.
11. Ando S, Suzuki M, Yamamoto N, et al. The prognostic value of both neuron-specific enolase (NSE) and Cyfra 21-1 in small cell lung cancer. Anticancer Res. 2004;24:1941-1946.
12. Molina R, Filella X, Auge JM, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumor Biol. 2003;24:209-218.
13. Ruibal A, Nunez MI, Rodriguez J, et al. Cytosolic levels of neuron-specific enolase in squamous cell carcinomas of the lung. Int J Biol Marker. 2003;18:188-194.
14. Pujol JL, Boher JM, Grenier J, et al. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Lung Cancer. 2001;31:221-231.
15. Body JJ, Paesmans M, Sculier JP, et al. Monoclonal immuno-radiometric assay polyclonal radio-immunoassay compared for neuron-specific enolase in patients with lung cancer. Clin Chem. 1992;38:748-751.
16. Boher JM, Pujol JL, Grenier J, et al. Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis. Br J Cancer. 1999;79:1419-1427.
17. Diez M, Torres A, Ortega L, et al. Value of serum neuron-specific enolase in non-small cell lung cancer. Oncology. 1993;50:127-131.
18. Kashiwabara K, Nakamura H, Esaki T. Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and cytokeratin 19 fragment levels. Clin Chim Acta. 2000;294:105-113.
19. Niklinski J, Chycewska E, Furman M, et al. Usefulness of a multiple biomarker assay in bronchoalveolar lavage (BAL) and serum for the diagnosis of small cell lung cancer. Neoplasm. 1993;40:305-308.
20. Watine J, Charet JC. Primary small-cell bronchial cancer: value of serum tumor markers in the prognostic evaluation. Presse Med. 1999;28:1541-1546.
21. Barlesi F, Gimenez C, Torre JP, et al. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med. 2004;98:357-362.
22. Pauwels RA, Buist AS, Calverley PM, et al. The Gold Scientific Committee: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med. 2001;163:1256-1276.
23. Haslam PL. BAL standardization and measurement of acellular components. Eur Respir Rev. 1998;8:1066-1071.
24. Klech H, Hutter C. Clinical guidelines and indications for bronchoalveolar lavage (BAL): report of European Society of Pneumology Task Group on BAL. Eur Respir J. 1990;3:937-974.
25. Martinek RG. Review of methods for determining urea nitrogen in biologic fluids. J Am Med Technol. 1969;31:678.
26. Rennard SI, Basset G, Lecossier D. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol. 1986;60:532-538.
27. Splinter TAW, Carney DN, Teeling M, et al. Levels of neuron-specific enolase after chemotherapy do not predict a response in small cell lung cancer. J Cancer Res Clin Oncol. 1988;114:641-643.
28. Hatzakis KD, Froudarakis ME, Bouros D, et al. Prognostic value of serum tumor markers in patients with lung cancer. Respiration. 2002;69:25-29.
29. Paone G, Angelis D, Greco S, et al. Evaluation of response to chemotherapy in patients affected with non-small cell lung cancer by means of three tumor markers elaborated by discriminant analysis. Respir Med. 1997;91:361-367.
30. Prados MC, Alverez-Sala RA, Blasca R, et al. The clinical value of neuron-specific enolase as a tumor marker in bronchoalveolar lavage. Cancer. 1994;74:1552-1555.
31. Graziano SL, Mazid R, Newman N, et al. The use of neuro-endocrine immuno peroxidase markers to predict chemotherapy response in patients with non-small cell lung cancer. J Clin Oncol. 1989;7:1398-1406.
32. Escuin JSC, Jiminez FM, Vicente CD, et al. The usefulness of serum neuron-specific enolase in the clinical management of small-cell lung carcinoma. Arch Broncopneumol. 1994;30:375-380.
33. Jorgensen LG, Osterlind K, Hansen H, et al. Serum neuron-specific enolase in progressive small cell lung cancer. Br J Cancer. 1994;70:759-761.
34. Nitta T, Fukuoka M, Masuda N, et al. Significance of serum neuron-specific enolase as a predictor of relapse of small-cell lung cancer. Jpn J Clin Oncol. 1995;25:179-183.
35. Spinazzi A, Soresi E, Boffi R, et al. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryogenic antigen as markers for staging and monitoring response to therapy of lung cancer. Cancer Detect Prev. 1994;18:209-220.
36. Collazos J, Esteban C, Fernandez A, et al. Measurement of the serum tumor marker neuron-specific enolase in patients with benign pulmonary diseases. Am J Respir Crit Care Med. 1994;150:143-145.
37. van Zandwijk N, Jassem E, Bonfrer JM, et al. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer. Semin Oncol. 1992;19(suppl 2):37-43.
38. Ferrigno D, Buccheri G, Giordano C. Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC). Lung Cancer. 2003;41:311-320.
39. Fujita K, Haimoto H, Imaizumi M, et al. Evaluation of gamma enolase as a tumor marker for lung cancer. Cancer. 1987;60:362-369.
40. Kalomenidis I, Dimakou K, Kolintza A, et al. Sputum carcinoembryonic antigen, neuron-specific enolase and cytokeratin fragment 19 levels in lung cancer diagnosis. Respirology. 2004;9:54-59.
41. Petersson T, Klockars M, Fröseth B. Neuron-specific enolase in the diagnosis of small cell lung cancer with pleural effusion: a negative report. Eur Respir J. 1988;1:698-700.
42. Macchia V, Mariano A, Cavalcanti M, et al. Tumor markers and lung cancer: correlation between serum and bronchial secretion levels of CEA, TPA, Can Ag CA-50, NSE and ferritin. Int J Biol Marker. 1987;2:151-156.
43. Gomez de Terreros Caro FJ, Alvarez-Sala R, Prados MC, et al. How to express tumor markers in bronchoalveolar lavage. Int J Biol Marker. 2004;19:67-71.